lifestyle.newsblaze.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Ensysce Biosciences
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
April 16, 2026
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
April 7, 2026
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
March 31, 2026
Ensysce Biosciences Initiates Live “Ask Me Anything” (AMA) Session Highlighting Growth and Future Plans
March 4, 2026
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
March 3, 2026
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
February 25, 2026
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
February 23, 2026
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 28, 2026
Ensysce Biosciences Expands Global Opioid Patent Portfolio
January 21, 2026
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
January 8, 2026
1
2
Next Page
→